Orbital Therapeutics
Enhancing RNA-based medicines
- 21-100 employees
- Healthcare
- B2B
- Biology
- SaaS
- MedTech
- Mid-Cambridge, Cambridge, MA
Jump to section
Company mission
To enhance global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible.
Our take
Orbital Therapeutics is building a first-of-its-kind RNA platform that is set to expand the applicability of RNA-based medicines across a range of human diseases, next-generation vaccines, immunomodulation, and protein replacement. Operating at the intersection of RNA technology delivery methods, data science, and automation, the company is well set to disrupt the industry with its innovative tech.
The vast potential of RNA-based therapeutics has the ability to alter the future of medicine and how diseases are treated, however, there are various barriers that keep companies from being able to deliver on the opportunities afforded by RNA medicines. Orbital was founded to provide such companies with the know-how and technological and biological insights needed to reach the full potential of RBA-based medicines.
The company has raised significant capital, its most recent led by ARCH Venture Partners, to advance its portfolio of programmable RNA to expand overall RNA -based applications. With a platform capable of changing how diseases are treated around the globe, Orbital is well set to see growth.
Freddie
Company Specialist at Welcome to the Jungle
Funding (1 round)
Apr 2023
$270m
SERIES A
Total funding: $270m
This company has top investors
Leadership
Ron Philip
(CEO & Director)Prior to Orbital. Ron spent 7 years at Spark Therapeutics as Senior VP/Head of Global Commercial, CCO, COO, and CEO. Prior to that, they spent 10 years at Pfizer multiple Strategy roles. They also spent 6 years at Deloitte as a Senior Manager of Strategy and Operatons.